Atsushi Senda, Hiroshi Suginaka, Koji Morishita, Kiyohide Fushimi
{"title":"Clinical outcomes of endovascular interventions for cerebral venous thrombosis in Japan: a nationwide retrospective study.","authors":"Atsushi Senda, Hiroshi Suginaka, Koji Morishita, Kiyohide Fushimi","doi":"10.1136/svn-2024-003639","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Cerebral venous thrombosis (CVT) is a rare but serious disease. Despite anticoagulation being the cornerstone therapy, some patients experience worsening disease, necessitating alternative treatment. Endovascular treatment is an anticipated option with an uncertain clinical relevance. The aim of this study was to assess the clinical effects and efficacy of endovascular therapy and identify patient populations that may benefit from treatment.</p><p><strong>Patients and methods: </strong>This retrospective study examined patient data from April 2014 to March 2022 that were extracted from a nationwide Japanese Diagnosis Procedure Combination database. The primary outcome was in-hospital mortality. The secondary outcomes included modified Rankin Scale (mRS) scores and post-hospitalisation complications of cerebral infarction and intracranial haemorrhage. Severity was adjusted using a generalised linear mixed model, and propensity-score matching was employed to compare outcomes between treatment groups.</p><p><strong>Results: </strong>The study included 2901 patients; 240 patients in the endovascular treatment group were matched with 240 patients in the standard treatment group. After adjusting for background factors, endovascular treatment did not improve in-hospital mortality (adjusted OR 1.45; 95% CI 0.74 to 2.16) or the mRS score (adjusted OR 0.89, 95% CI 0.56 to 1.23). No subpopulations that could benefit from endovascular treatment were identified. Post-hospitalisation cerebral infarction and intracranial haemorrhage did not increase with endovascular treatment (0.8% in the endovascular treatment group vs 1.2% in the standard treatment group).</p><p><strong>Conclusion: </strong>Endovascular treatment showed no significant benefit for patients with CVT, indicating that treatment guidelines need to be refined. Our findings can guide clinical decisions and suggest the necessity of further research on potential benefits in specific subpopulations.</p>","PeriodicalId":48733,"journal":{"name":"Journal of Investigative Medicine","volume":" ","pages":""},"PeriodicalIF":2.6000,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Investigative Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1136/svn-2024-003639","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Cerebral venous thrombosis (CVT) is a rare but serious disease. Despite anticoagulation being the cornerstone therapy, some patients experience worsening disease, necessitating alternative treatment. Endovascular treatment is an anticipated option with an uncertain clinical relevance. The aim of this study was to assess the clinical effects and efficacy of endovascular therapy and identify patient populations that may benefit from treatment.
Patients and methods: This retrospective study examined patient data from April 2014 to March 2022 that were extracted from a nationwide Japanese Diagnosis Procedure Combination database. The primary outcome was in-hospital mortality. The secondary outcomes included modified Rankin Scale (mRS) scores and post-hospitalisation complications of cerebral infarction and intracranial haemorrhage. Severity was adjusted using a generalised linear mixed model, and propensity-score matching was employed to compare outcomes between treatment groups.
Results: The study included 2901 patients; 240 patients in the endovascular treatment group were matched with 240 patients in the standard treatment group. After adjusting for background factors, endovascular treatment did not improve in-hospital mortality (adjusted OR 1.45; 95% CI 0.74 to 2.16) or the mRS score (adjusted OR 0.89, 95% CI 0.56 to 1.23). No subpopulations that could benefit from endovascular treatment were identified. Post-hospitalisation cerebral infarction and intracranial haemorrhage did not increase with endovascular treatment (0.8% in the endovascular treatment group vs 1.2% in the standard treatment group).
Conclusion: Endovascular treatment showed no significant benefit for patients with CVT, indicating that treatment guidelines need to be refined. Our findings can guide clinical decisions and suggest the necessity of further research on potential benefits in specific subpopulations.
简介脑静脉血栓(CVT)是一种罕见但严重的疾病。尽管抗凝是治疗的基础,但一些患者的病情仍在恶化,需要采取其他治疗方法。血管内治疗是一种预期中的选择,但其临床意义尚不确定。本研究旨在评估血管内治疗的临床效果和疗效,并确定可能从治疗中获益的患者人群:这项回顾性研究研究了2014年4月至2022年3月期间的患者数据,这些数据提取自日本全国范围内的诊断程序组合数据库。主要结果是院内死亡率。次要结果包括改良Rankin量表(mRS)评分以及脑梗塞和颅内出血等住院后并发症。采用广义线性混合模型对严重程度进行调整,并采用倾向分数匹配法对不同治疗组的结果进行比较:研究共纳入2901名患者;血管内治疗组的240名患者与标准治疗组的240名患者进行了配对。调整背景因素后,血管内治疗并未改善院内死亡率(调整后 OR 1.45;95% CI 0.74 至 2.16)或 mRS 评分(调整后 OR 0.89,95% CI 0.56 至 1.23)。未发现可从血管内治疗中获益的亚人群。入院后脑梗死和颅内出血并未因血管内治疗而增加(血管内治疗组为0.8%,标准治疗组为1.2%):结论:血管内治疗对CVT患者无明显益处,这表明治疗指南需要改进。我们的研究结果可为临床决策提供指导,并表明有必要进一步研究特定亚群的潜在益处。
期刊介绍:
Journal of Investigative Medicine (JIM) is the official publication of the American Federation for Medical Research. The journal is peer-reviewed and publishes high-quality original articles and reviews in the areas of basic, clinical, and translational medical research.
JIM publishes on all topics and specialty areas that are critical to the conduct of the entire spectrum of biomedical research: from the translation of clinical observations at the bedside, to basic and animal research to clinical research and the implementation of innovative medical care.